Drug Res (Stuttg) 2015; 65(S 01): S14-S15
DOI: 10.1055/s-0035-1558064
Symposium der Paul-Martini-Stiftung
Georg Thieme Verlag KG Stuttgart · New York

From Bone Cell Biology to Novel Therapies of Osteoporosis

L. C. Hofbauer
Medizinische Klinik u. Poliklinik III, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden
› Author Affiliations
Further Information

Publication History

Publication Date:
04 November 2015 (online)

Osteoporosis is a common disease characterised by a systemic impairment of bone mass and microarchitecture that results in fragility fractures. With an ageing population, the medical impact of osteoporosis will increase further. A detailed knowledge of bone biology with molecular insights into the communication between bone-forming osteoblasts and bone-resorbing osteoclasts and the orchestrating signalling network has led to the identification of novel therapeutic targets. Based on this, novel treatment strategies have been developed aimed at inhibiting excessive bone resorption and increasing bone formation. The most promising novel treatments include denosumab, a monoclonal antibody against receptor activator of NF-κB ligand, a key osteoclast cytokine, odanacatib, a specific inhibitor of the osteoclast protease cathepsin K, and antibodies against the sclerostin, an endogenous inhibitor of bone formation.